Polaris AI Pharma to Join Korea's Largest Medical AI Alliance, "Medical AI Alliance"

Polaris AI Pharma, which has been preparing new AI-based businesses since joining the Polaris Office Group, announced on August 12 that it has embarked on building the next-generation medical data platform, "LIFE Network," in collaboration with the Medical AI Alliance (MAA), a coalition of leading publicly listed companies in Korea's medical AI sector.

This alliance brings together a large number of companies at the forefront of Korea's bio and medical AI industries, and plans to recruit additional partners to further advance the platform.

MAA includes Polaris AI Pharma, VUNO, Selvas AI, Selvas Healthcare, Mediana, HLB Global, JLK, LabGenomics, and others, pooling each company's core competencies.

In particular, Polaris AI Pharma will leverage its manufacturing, quality, and process data, as well as pipeline management capabilities gained from its main businesses in active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), to participate in defining and validating pharmaceutical R&D-specialized datasets within the platform.

MAA's core strategy is to generate synergy through this "alliance." The group expects this approach to secure a unique competitive edge against global big tech companies such as Google and Microsoft.

MAA emphasized that by combining data from the diverse medical device launches and medical AI solution analyses of its member companies, it will be able to secure the largest volume of medical AI data in Korea. The alliance plans to develop the "LIFE Network" platform to integrate not only each company's proprietary data but also individuals' health information, treatment history (medical MyData), and daily activity records (lifelog).

The "LIFE Network" aims to go beyond simple data training by applying a neuro-symbolic AI model that combines inference, with plans to deliver innovative outcomes. According to MAA, this will enable the discovery of hidden patterns in vast medical datasets and the integration of AI capabilities that mimic human reasoning.

MAA intends to further enhance the platform through partnerships with key companies across Asia and is also targeting global market expansion. To this end, it is in discussions with hospitals and healthcare companies, accelerating the expansion of its data ecosystem.

A representative from Polaris AI Pharma stated, "LIFE Network can be expanded into various fields, including personalized medical services and risk assessment for insurance companies. Through MAA, we expect to predict the success probability of drug candidates and optimize clinical trial design, dramatically reducing R&D time and costs." The representative added, "We aim to improve public health while simultaneously enhancing the nation's bio-industry competitiveness."

Meanwhile, Polaris AI Pharma continues to operate its core generic-based API and CDMO businesses stably and, since joining the Polaris Office Group, has been working with Polaris Office to expand into software-driven, AI-based pharmaceutical R&D data businesses.

This content was produced with the assistance of AI translation services.